HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: an open pilot study.

AbstractOBJECTIVE:
Gastric antral vascular ectasia (GAVE) is a rare cause of chronic bleeding in cirrhotic patients. Treatment of GAVE with surgical or nonsurgical portal decompression, beta-blockers, or endoscopic therapy provides disappointing results. In the present study, we evaluated the efficacy of estrogen-progesterone therapy, which has been reported to control chronic bleeding in gastrointestinal vascular malformations, such as Osler-Weber Rendu disease or angiodysplasia, in GAVE-related chronic bleeding.
METHODS:
Six cirrhotic patients who bled chronically from GAVE were included. Three had alcoholic cirrhosis, two cryptogenic cirrhosis, and one primary biliary cirrhosis. Grade 1 esophageal varices were noted in four patients. Bleeding could not be controlled by beta-blockers, and endoscopic therapy was not considered given the extension of the antral vascular lesions.
RESULTS:
Before the start of therapy, transfusion requirements averaged 3.5 units/month over a 1.5-11 month period of observation. Patients were then treated with a combination of ethynil estradiol 30 microg and noretisterone 1.5 mg daily. During follow-up (range 3-12 months), bleeding did not recur in four patients; in one patient, treatment with estrogen progesterone decreased the need for transfusions from 4 units/month to 1.4 unit/month; this patient stopped the treatment inadvertently after 6 months and severe anemia recurred with a need for 4 units of blood in the following month; reintroduction of the treatment resulted in an increase of hemoglobin levels without the need for blood transfusions during the following 4 months. In the last patient, a 5-month treatment did not improve chronic bleeding.
CONCLUSIONS:
The present study suggests that estrogen-progesterone therapy is useful in the treatment of chronic bleeding related to GAVE; however, these findings require confirmation by a controlled trial.
AuthorsA Tran, J P Villeneuve, M Bilodeau, B Willems, D Marleau, D Fenyves, R Parent, G Pomier-Layrargues
JournalThe American journal of gastroenterology (Am J Gastroenterol) Vol. 94 Issue 10 Pg. 2909-11 (Oct 1999) ISSN: 0002-9270 [Print] United States
PMID10520843 (Publication Type: Journal Article)
Chemical References
  • Estradiol Congeners
  • Progesterone Congeners
  • Ethinyl Estradiol
  • Norethindrone Acetate
  • Norethindrone
Topics
  • Aged
  • Aged, 80 and over
  • Chronic Disease
  • Drug Evaluation
  • Drug Therapy, Combination
  • Estradiol Congeners (administration & dosage)
  • Ethinyl Estradiol (administration & dosage)
  • Gastric Antral Vascular Ectasia (complications)
  • Gastrointestinal Hemorrhage (drug therapy)
  • Humans
  • Liver Cirrhosis (complications)
  • Middle Aged
  • Norethindrone (administration & dosage, analogs & derivatives)
  • Norethindrone Acetate
  • Pilot Projects
  • Progesterone Congeners (administration & dosage)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: